Semaglutide, which belongs to the family of incretin glucagon-like peptide-1 receptor agonists (GLP-1 RAs), is a peptide approved for the long-term treatment of type 2 diabetes (T2DM) and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.